Compare AIRI & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRI | CTXR |
|---|---|---|
| Founded | 1979 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 13.4M |
| IPO Year | 2013 | 2010 |
| Metric | AIRI | CTXR |
|---|---|---|
| Price | $2.65 | $0.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 34.4K | ★ 275.1K |
| Earning Date | 11-09-2026 | 12-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.39 | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $47,921,000.00 | N/A |
| Revenue This Year | $4.34 | N/A |
| Revenue Next Year | N/A | $104.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.30 | $0.37 |
| 52 Week High | $3.95 | $1.54 |
| Indicator | AIRI | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 48.14 | 52.02 |
| Support Level | $2.50 | $0.52 |
| Resistance Level | $2.75 | $0.63 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 50.53 | 52.08 |
Air Industries Group is an aerospace and defense company. Its manufacturers of precision components and assemblies for large aerospace and defense prime contractors. The company products include landing gears, flight controls, engine mounts and components for aircraft jet engines, ground turbines and other complex machines. The ultimate end-user of products is the U.S. Government, international governments, and commercial global airlines.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.